(IMO) Imperial Oil - Overview
Stock: Crude Oil, Natural Gas, Refined Fuels, Petrochemicals, Lubricants
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.65% |
| Yield on Cost 5y | 11.71% |
| Yield CAGR 5y | 25.94% |
| Payout Consistency | 92.0% |
| Payout Ratio | 29.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 32.5% |
| Relative Tail Risk | 1.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.86 |
| Alpha | 63.12 |
| Character TTM | |
|---|---|
| Beta | 0.746 |
| Beta Downside | 1.008 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.95% |
| CAGR/Max DD | 1.42 |
Description: IMO Imperial Oil January 29, 2026
Imperial Oil Ltd (NYSE MKT: IMO) is a fully integrated Canadian energy company operating upstream, downstream and chemical businesses. The upstream arm extracts crude oil, natural gas, synthetic crude and bitumen; the downstream segment refines, transports, blends and markets petroleum products under the Esso and Mobil brands; and the chemical division produces aliphatic solvents, plasticizer intermediates, polyethylene resins and refinery-grade propylene. The firm is a subsidiary of Exxon Mobil and has been in operation since 1880, with headquarters in Calgary.
Key recent metrics (as of Q3 2025): production averaged 281 kboe/d, a 3 % YoY increase driven by higher bitumen output in the Athabasca region; refining margins rose to US$ 16.2 per barrel, reflecting a narrowing Canadian differential and improved utilization at the Montreal refinery; and the company paid a quarterly dividend of C$ 0.38 per share, yielding roughly 5.3 % on current price. Capital expenditures for 2025 are projected at C$ 5.6 billion, split roughly 60 % upstream and 40 % downstream, underscoring a balanced growth strategy.
Sector-wide, Canadian integrated producers are currently benefiting from OPEC+ supply discipline that supports global crude prices, while the domestic price spread (CDA) has tightened to its narrowest level since 2020, enhancing downstream profitability. For analysts seeking a deeper, data-driven valuation framework, a quick look at ValueRay’s proprietary model may surface additional insight worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 3.27b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 5.66 > 1.0 |
| NWC/Revenue: 5.02% < 20% (prev 4.81%; Δ 0.22% < -1%) |
| CFO/TA 0.22 > 3% & CFO 6.71b > Net Income 3.27b |
| Net Debt (3.03b) to EBITDA (6.84b): 0.44 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (490.4m) vs 12m ago -5.05% < -2% |
| Gross Margin: 14.47% > 18% (prev 0.14%; Δ 1433 % > 0.5%) |
| Asset Turnover: 123.6% > 50% (prev 113.7%; Δ 9.92% > 0%) |
| Interest Coverage Ratio: 354.8 > 6 (EBITDA TTM 6.84b / Interest Expense TTM 12.0m) |
Altman Z'' 3.01
| A: 0.07 (Total Current Assets 7.15b - Total Current Liabilities 4.86b) / Total Assets 30.85b |
| B: 0.53 (Retained Earnings 16.48b / Total Assets 30.85b) |
| C: 0.12 (EBIT TTM 4.26b / Avg Total Assets 36.89b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 13.84b) |
| Altman-Z'' Score: 3.01 = A |
What is the price of IMO shares?
Over the past week, the price has changed by +11.20%, over one month by +26.54%, over three months by +20.36% and over the past year by +70.73%.
Is IMO a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 10
- Sell: 2
- StrongSell: 1
What are the forecasts/targets for the IMO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.9 | -31.9% |
| Analysts Target Price | 77.9 | -31.9% |
| ValueRay Target Price | 160.6 | 40.4% |
IMO Fundamental Data Overview February 09, 2026
P/E Forward = 24.3309
P/S = 1.1929
P/B = 3.1455
P/EG = 0.85
Revenue TTM = 45.60b USD
EBIT TTM = 4.26b USD
EBITDA TTM = 6.84b USD
Long Term Debt = 3.45b USD (from longTermDebt, two quarters ago)
Short Term Debt = 81.1m USD (from shortTermDebt, two quarters ago)
Debt = 3.03b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 3.03b USD (using Total Debt 3.03b, CCE unavailable)
Enterprise Value = 59.19b USD (56.16b + Debt 3.03b - (null CCE))
Interest Coverage Ratio = 354.8 (Ebit TTM 4.26b / Interest Expense TTM 12.0m)
EV/FCF = 12.59x (Enterprise Value 59.19b / FCF TTM 4.70b)
FCF Yield = 7.94% (FCF TTM 4.70b / Enterprise Value 59.19b)
FCF Margin = 10.31% (FCF TTM 4.70b / Revenue TTM 45.60b)
Net Margin = 7.16% (Net Income TTM 3.27b / Revenue TTM 45.60b)
Gross Margin = 14.47% ((Revenue TTM 45.60b - Cost of Revenue TTM 39.00b) / Revenue TTM)
Gross Margin QoQ = 17.04% (prev 11.20%)
Tobins Q-Ratio = 1.92 (Enterprise Value 59.19b / Total Assets 30.85b)
Interest Expense / Debt = 0.26% (Interest Expense 8.01m / Debt 3.03b)
Taxrate = 21.78% (136.9m / 628.5m)
NOPAT = 3.34b (EBIT 4.26b * (1 - 21.78%))
Current Ratio = 1.47 (Total Current Assets 7.15b / Total Current Liabilities 4.86b)
Debt / Equity = 0.18 (Debt 3.03b / totalStockholderEquity, two quarters ago 17.01b)
Debt / EBITDA = 0.44 (Net Debt 3.03b / EBITDA 6.84b)
Debt / FCF = 0.65 (Net Debt 3.03b / FCF TTM 4.70b)
Total Stockholder Equity = 22.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.85% (Net Income 3.27b / Total Assets 30.85b)
RoE = 14.53% (Net Income TTM 3.27b / Total Stockholder Equity 22.47b)
RoCE = 16.45% (EBIT 4.26b / Capital Employed (Equity 22.47b + L.T.Debt 3.45b))
RoIC = 11.99% (NOPAT 3.34b / Invested Capital 27.83b)
WACC = 8.24% (E(56.16b)/V(59.19b) * Re(8.67%) + D(3.03b)/V(59.19b) * Rd(0.26%) * (1-Tc(0.22)))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.22%
[DCF Debug] Terminal Value 78.22% ; FCFF base≈4.47b ; Y1≈4.78b ; Y5≈5.78b
Fair Price DCF = 192.1 (EV 95.94b - Net Debt 3.03b = Equity 92.91b / Shares 483.6m; r=8.24% [WACC]; 5y FCF grow 7.74% → 2.90% )
EPS Correlation: -31.01 | EPS CAGR: 3.21% | SUE: 0.16 | # QB: 0
Revenue Correlation: -61.52 | Revenue CAGR: -2.01% | SUE: -0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.57 | Chg30d=-0.068 | Revisions Net=-3 | Analysts=5
EPS current Year (2026-12-31): EPS=6.74 | Chg30d=-0.416 | Revisions Net=-4 | Growth EPS=-20.9% | Growth Revenue=-10.7%
EPS next Year (2027-12-31): EPS=7.49 | Chg30d=-0.354 | Revisions Net=+0 | Growth EPS=+11.1% | Growth Revenue=+24.3%